创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

范启林, 郑侠, 张玉彬. 基于免疫代谢信号通路的非酒精性脂肪性肝炎的研究及中药干预[J]. 药学进展, 2018, 42(3): 201-206.
引用本文: 范启林, 郑侠, 张玉彬. 基于免疫代谢信号通路的非酒精性脂肪性肝炎的研究及中药干预[J]. 药学进展, 2018, 42(3): 201-206.
FAN Qilin, ZHENG Xia, ZHANG Yubin. Immunometabolic Signaling Pathways Based Researches on Non-alcoholic Steatohepatitis and Intervention by Traditional Chinese Medicines[J]. Progress in Pharmaceutical Sciences, 2018, 42(3): 201-206.
Citation: FAN Qilin, ZHENG Xia, ZHANG Yubin. Immunometabolic Signaling Pathways Based Researches on Non-alcoholic Steatohepatitis and Intervention by Traditional Chinese Medicines[J]. Progress in Pharmaceutical Sciences, 2018, 42(3): 201-206.

基于免疫代谢信号通路的非酒精性脂肪性肝炎的研究及中药干预

Immunometabolic Signaling Pathways Based Researches on Non-alcoholic Steatohepatitis and Intervention by Traditional Chinese Medicines

  • 摘要: 非酒精性脂肪性肝炎(NASH)是日益普遍的全球性代谢性肝损伤,可能由遗传因素、多重代谢紊乱等多因素共同引起,其确切的发病机制尚未明确。目前NASH的治疗方法主要是控制代谢状态、改变生活方式,但长期依从性很低,也不适用于所有NASH患者。传统中药不但具有抗氧化、抗炎和降低血脂等多种生物学功能,在临床研究中还表现出疗效较好、毒副作用较低的显著优势。主要从免疫代谢方面综述NASH的研究进展及中药干预,为深入研究NASH的药物治疗提供新靶点和新思路。

     

    Abstract: Non-alcoholic steatohepatitis (NASH) is an increasingly common metabolic liver injury worldwide. It is probably caused by various factors including genetic factors and multiple metabolic disorders, although the exact pathogenesis is still unclear. Currently the mainstay treatment of NASH aims at controlling metabolic state and changing lifestyle. However, its long-term compliance is very low, and not applicable to all NASH patients. Traditional Chinese medicines not only have multiple biological functions such as anti-oxidative, anti-inflammatory and lipid-lowering activity, but also show obvious advantages in clinical research with better efficacy and less side effects. This article reviewed the research progress in NASH from the perspective of immune metabolism and its intervention by traditional Chinese medicine, so as to provide new targets and ideas for further study of NASH therapy.

     

/

返回文章
返回